Journal: Cancer research
This study addresses a key limitation in CRISPR/Cas9 gene knockout research within cancer immunology. Persistent expression of exogenous elements, like Cas9 and resistance markers, can cause excessive tumor immune rejection. This leads to experimental variability and failures.
The authors developed the v2-Blast-lox2272 (VL)-adenovirus expressing Cre recombinase (AdCre) system, which efficiently excises these exogenous components after gene knockout.
This approach:
- Reduces tumor immune rejection in allograft models
- Simplifies experimental processes
- Improves data reliability
The optimized VL-AdCre system thus provides a robust and practical tool for in vivo gene function studies and advancing immunotherapy research.